Parexel picks a chief scientist to guide a transition

CRO Parexel International ($PRXL) has been working to better unify its disparate service divisions, and now the company has named its first chief scientific officer to oversee its end-to-end offerings. Sy Pretorius, a medical doctor and 18-year Parexel veteran, will take the helm and steer the CRO's efforts in innovation, working to align the company's segments as they grow. Pretorius currently serves as vice president and head of early phase research, a role he will retain. More

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.